Yahoo Finance VentriPoint Diagnostics Third Quarter 2023 Earnings: CA$0.007 loss per share (vs CA$0.009 loss in 3Q 2022)
VentriPoint Diagnostics (CVE:VPT) Third Quarter 2023 Results
Key Financial Results
Net loss: CA$1.17m (loss narrowed by 16% from 3Q 2022).
CA$0.007 loss per share (improved from CA$0.009 loss in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
VentriPoint Diagnostics shares are up 33% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 5 warning signs for VentriPoint Diagnostics (of which 3 don't sit too well with us!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
